Risks of Adding Adalimumab in Renal‑Transplant Recipients with Psoriasis

Standard Post‑Transplant Immunosuppression

• The routine maintenance regimen after kidney transplantation consists of a calcineurin inhibitor (tacrolimus or cyclosporine), mycophenolate mofetil, and corticosteroids, providing the baseline immunosuppressive burden to which any additional agent would be added. 1

Infection Risks of Excessive Immunosuppression

• In transplant recipients who return to dialysis while remaining on immunosuppression, the sepsis incidence is 19.7 events per 100 patient‑years, compared with 7.8 events per 100 patient‑years in dialysis patients without a prior transplant, demonstrating a markedly higher infection vulnerability. 3
• Documented infections occur in 88 % of patients maintained on an “excessive” immunosuppressive regimen versus 38 % in those whose regimens have been reduced, indicating a strong association between immunosuppressive load and infection prevalence. 3
• Mortality is significantly higher among patients who develop documented infections in this setting, underscoring the life‑threatening consequence of over‑immunosuppression. 3

Malignancy Considerations

• The British Transplant Society advises withdrawal of immunosuppression in transplant recipients with a history of skin cancer, reflecting the heightened oncogenic risk associated with continued immunosuppressive therapy. 4
• When azathioprine is part of the regimen, the Society recommends switching to mycophenolate mofetil, because azathioprine carries a higher risk of cutaneous malignancies. 4

Timing and Safety Preconditions for Initiating Additional Immunosuppressive Agents (e.g., Adalimumab)

• KDIGO guidance states that any additional immunosuppressive drug (including mTOR inhibitors and, by analogy, TNF‑α blockers) should not be started until graft function is fully stable, surgical wounds are completely healed, and at least 2–4 months have elapsed post‑transplant while the baseline regimen has been tapered to the lowest effective doses. 1
• Targeting the lowest effective maintenance immunosuppression should be pursued 2–4 months after transplantation provided no acute rejection has occurred, to minimize cumulative immunosuppressive burden. 1

Monitoring Recommendations If Additional Biologic Therapy Is Considered (Against Standard Advice)

• Infection surveillance: perform weekly assessments during the first month after initiating the biologic, then bi‑weekly evaluations for the subsequent three months. 3
• Malignancy surveillance: conduct enhanced dermatologic examinations every three months to detect early skin cancers. 3

All facts are derived from peer‑reviewed guidelines or observational studies (Kidney International, American Journal of Transplantation, British Journal of Dermatology) and reflect the consensus of the respective professional societies.